 |
|||||
|
|||||
|
Confirmed title: Unique nanonisation technology for poorly soluble APIs by Nanoform
|
|||||
|
20 June: 10:45 - 11:00
|
|||||
|
Dr Niklas Sandler, Chief Technology Officer, Nanoform Finland Ltd
|
|||||
|
ABSTRACT
|
|||||
|
Our multi-patented and scalable Controlled Expansion of Supercritical Solutions (CESSᵀᴹ ) technology produces nanonized ‘designed-for-purpose’ API particles. This enables poorly soluble molecules in the pharmaceutical pipeline to progress into clinical development by increasing their rate of dissolution and improving their bioavailability. Our unique nanonizationᵀᴹ technology also provides novel opportunities in diverse value enhancing drug delivery applications. We work together with pharma and biotech partners globally to enhance molecules’ formulation performance through our best-in-class nanonizationᵀᴹservices. Nanoform’s platform technology can give failed drug molecules a second chance and gives an unique path to develop nanoparticles from early phase development onwards. The patented technology is based on supercritical CO2. The drug solution is expanded through a controlled process to produce pure drug nanoparticles. The process is more controlled than conventional supercritical technologies, and it produces smaller and more uniformly sized particles. This presentation will give an introduction Nanoforms technology and show the capabilities in small scale screening in early stage development and GMP manufacture of nanoparticles.
|
|||||
|
BIOGRAPHY
|
|||||
|
Chief Technology Officer at Nanoform Finland Ltd. since January 2019 leading the R&D and QC activities with a focus on further developing the company’s innovative manufacturing technology. Nanoform offers new technological and business advantages for the pharmaceutical industry. The company has developed a proprietary technology called Controlled Expansion of Supercritical Solutions (CESSTM) that allows nanonization of drug substances. Dr Sandler has a PhD from the University of Helsinki and he has worked in various roles both in the pharmaceutical industry and academia. He has more than 20-years of experience in pharmaceutical technology with the focus on manufacturing technologies, material science and process analytical technologies. He has run numerous academic and industrial R&D and commercialisation projects in the field successfully. He has been invited speaker in various international conferences and published more than 100 peer reviewed articles in international high-quality journals throughout the years.
|
|||||
|
COMPANY PROFILE
|
|||||
|
Nanoform Finland Ltd
|
|||||
|
Nanoform is an innovative nanoparticle medicine enabling company. We work together with pharma and biotech partners globally to reduce clinical attrition and enhance their molecules formulation performance through our best-in-class nanonizationᵀᴹ services. Our multi-patented and scalable Controlled Expansion of Supercritical Solutions (CESSᵀᴹ ) technology produces nanonized ‘designed-for-purpose’ API particles, as small as 10nm. This enables poorly soluble molecules in the pharmaceutical pipeline to progress into clinical development by increasing their rate of dissolution and improving their bioavailability. Nanoform’s unique nanonization™ technology will transform the pharma industry by initiating a new era of drug delivery applications.
|
Learn more about BOS2019
